Pharmaceutical firm Novo Nordisk The corporate is taking motion to rein within the extremely common compounded semaglutide business, which supplies copies of the blockbuster weight reduction medicine Ozempic and Wigovy to sufferers, usually at a lot decrease costs.
A Danish pharmaceutical firm is lobbying the U.S. Meals and Drug Administration so as to add semaglutide to the company’s Problem Compounding Record (DDC). This prevents dishing out pharmacies from manufacturing counterfeit merchandise of the drug. in The agency’s filing TuesdayNovo Nordisk’s legal professionals reasoned that semaglutide was included on these lists for causes together with “because of the complexities related to the formulation.”
“These medicine are inherently advanced to synthesize safely, and the dangers to affected person security far outweigh the advantages. to make sure that they solely obtain secure and efficient semaglutide merchandise,” mentioned Jamie Bennett, director of media relations at Novo Nordisk.
FDA spokeswoman Amanda Hills instructed WIRED in an e mail that the company is “reviewing the petition and intends to reply on to the petitioner.”
If authorized, this designation would have important implications for the compounding business and certain for the tens of millions of individuals at the moment taking compounded GLP-1 medicine.
GLP-1 injection medicine, together with semaglutide and tirzepatide, have been in brief provide since 2022 as a result of their reputation. In the US, when the FDA declares a drug in brief provide, sure licensed pharmacies promote “compound” variations which are blended in-house and are assumed to include the identical lively elements as the unique drug. are permitted to fabricate pharmaceutical merchandise.
Telemedicine suppliers are profiting from GLP-1 drug shortages and providing compounded variations to sufferers via fast digital appointments. The follow has brought on tensions with drug corporations that make branded medicine, as compounded variations are offered at a lot decrease costs. Ozempic and Wegovy value about $1,000 per thirty days with out insurance coverage, whereas mixture semaglutide is marketed on-line for as little as $100 per thirty days.
Not like generic medicine, that are manufactured after a drug’s patent has expired, mixture medicine wouldn’t have to be authorized by the FDA earlier than they’ll go in the marketplace. Which means that the FDA can not assure the security, effectiveness, or high quality of compounded medicine earlier than they’re offered to sufferers. FDA obtained the next Multiple reports of harmful side effectsrelated to potential dosing errors related to compounded semaglutide merchandise, together with hospitalization.
